BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER, AND METHODS THEREOF
    52.
    发明申请
    BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER, AND METHODS THEREOF 审中-公开
    用于诊断前列腺癌的生物标志物及其方法

    公开(公告)号:WO2007109881A8

    公开(公告)日:2007-12-13

    申请号:PCT/CA2007000469

    申请日:2007-03-23

    摘要: The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.

    摘要翻译: 本发明描述了一种用于预测指示前列腺癌存在的健康状态的方法。 该方法测量了具有未确定健康状态的患者的血液样本中特定的小生物化学物质(称为代谢物)的强度,并将这些强度与健康个体群体观察到的强度和/或先前观察到的强度进行比较 一组确诊的前列腺癌阳性个体。 该方法使得从业者能够确定筛查的患者对前列腺癌呈阳性的可能性。

    METHOD FOR DETECTING OVARIAN CANCER
    54.
    发明申请
    METHOD FOR DETECTING OVARIAN CANCER 审中-公开
    检测卵巢癌的方法

    公开(公告)号:WO2007061656A2

    公开(公告)日:2007-05-31

    申请号:PCT/US2006/043893

    申请日:2006-11-13

    IPC分类号: G01N33/574

    CPC分类号: G01N33/57449 G01N2405/04

    摘要: A method of detecting ovarian cancer in a female test subject comprising determining the amount of plasmenyl-PA or a biomarker having a mass charge ratio of approximately 655.3 in a sample of a bodily fluid taken from the female test subject and comparing the amount of plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject to a range of amounts of plasmenyl-PA (or the biomarker) found in samples of bodily fluids taken from a group of normal female subjects of the same species as the female test subject and lacking ovarian cancer, whereby a lower amount of the plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject indicates the presence of ovarian cancer.

    摘要翻译: 检测雌性测试对象中的卵巢癌的方法包括测定取自雌性测试的体液样品中plasmenyl-PA的量或质荷比约为655.3的生物标志物 并将来自雌性受试者的体液样品中plasmenyl-PA(或生物标志物)的量与从取自雌性受试者的体液样品中发现的一定量的plasmenyl-PA(或生物标志物) 从雌性受试者取得的体液样品中的plasmenyl-PA(或生物标志物)的量较少,表示雌性受试者为同一物种的正常雌性受试者并且缺乏卵巢癌, 卵巢癌。

    ASSAY FOR LOW MOLECULAR WEIGHT HEPARIN
    55.
    发明申请
    ASSAY FOR LOW MOLECULAR WEIGHT HEPARIN 审中-公开
    低分子重量蛋白测定

    公开(公告)号:WO2004016800A3

    公开(公告)日:2004-04-29

    申请号:PCT/US0321919

    申请日:2003-07-15

    摘要: A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is gamma-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37°C.

    摘要翻译: 提供了一种用于测定新鲜全血和抗凝血剂处理血液中低分子量肝素的凝血酶原时间试剂。 试剂由重组动物组织因子和合成磷脂的混合物组成,该混合物包含磷脂酰醇。 在配制试剂时使用包含灵敏度调节剂的制剂缓冲液。 重组动物组织因子包括兔脑。 该混合物的合成磷脂包括棕榈酰胆碱磷脂酰胆碱(POPC),棕榈酰叶酰磷脂酰丝氨酸(POPS)和磷脂酰醇。 磷脂酰胆固醇包括二油酰磷脂酰乙醇,二油酰磷脂酰基甲醇,二油酰磷脂酰丙醇,二油酰磷脂酰丁醇和二油酰磷脂酰肌醇。 制剂缓冲液中的灵敏度调节剂是γ-环糊精。 将配制的试剂风干,并在37℃下保持稳定至少3周。

    IMPROVED AUTOMATED LPA ASSAY AND METHODS OF DETECTING CANCER
    59.
    发明申请
    IMPROVED AUTOMATED LPA ASSAY AND METHODS OF DETECTING CANCER 审中-公开
    改进的自动LPA测定和检测癌症的方法

    公开(公告)号:WO01032916A2

    公开(公告)日:2001-05-10

    申请号:PCT/US2000/030280

    申请日:2000-11-02

    摘要: The present invention relates to an improved enzymatic diagnostic assay to detect carcinoma by measuring various lysophospholipids, including lysophosphatidic acid (LPA), in a patient. In a preferred embodiment, this assay measures the human plasma level of LPA in an automated format with a minimal number of reagents and with reduced incubation periods. The present invention also comprises several additional technical improvements to the current LPA assays disclosed in the prior art.

    摘要翻译: 本发明涉及通过测量患者中各种溶血磷脂(包括溶血磷脂酸(LPA))来检测癌症的改进的酶学诊断测定法。 在优选的实施方案中,该测定法以最小数量的试剂和减少的潜伏期以自动化形式测量LPA的人血浆水平。 本发明还包括对现有技术中公开的当前LPA测定法的若干附加技术改进。